PBMWW — Psyence Biomedical Ltd. Warrant
$0.0151-6.21%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PBMWW in the TickerWise workspace.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ
- Website: https://www.psyencebiomed.com
Latest SEC filings for PBMWW
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.